Sign in4 stories
The company said topline interim results from its pivotal FORTIFI-HN01 study are expected in mid-2027, while cash on hand is projected to fund operations into the first half of 2029.
SEC filing (3)
The company reported third-quarter 2026 results alongside an FDA submission, a trial closure expected to save up to $125 million, and $1.15 billion in cash.
SEC filing (14)
The company said topline data from the placebo-controlled study in mild Alzheimer's disease are expected in the first quarter of 2027.
SEC filing (2)
The clinical-stage immunology company priced an undisclosed share count as of October 5, 2026, with stock last trading at $93.19.
SEC filing (3)